E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Elderly patients (>= 70 years) undergoing intermediate- or high-risk non-cardiac surgery |
|
E.1.1.1 | Medical condition in easily understood language |
postoperative anaemia in elderly patients |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 27.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10048861 |
E.1.2 | Term | Anaemia postoperative |
E.1.2 | System Organ Class | 10022117 - Injury, poisoning and procedural complications |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate if in a geriatric population, a liberal strategy reduces the occurrence of major adverse events after non-cardiac surgery compared to a restrictive transfusion strategy within 90 days after surgery. The primary efficacy outcome is defined as a composite of: I. All-cause mortality defined as death from any cause II. Acute myocardial infarction confirmed by cardiologist III. Acute ischaemic stroke confirmed by neurologist IV. Acute kidney injury (stage III) defined according to the Kidney Disease Improving Global Outcomes criteria: Increase plasma creatinine level >= 3 times within 7 days or initiation of RRT V. Acute mesenteric ischaemia (ischaemia confirmed by intervention) VI. Acute peripheral vascular ischaemia defined as a new non-thrombotic compromised circulation in a limb confirmed by angiography and/or leading to surgery After hospital discharge, events of composite outcome will only be considered as present if they lead to hospital re-admission or death. |
|
E.2.2 | Secondary objectives of the trial |
Liberal transfusion strategy: - reduces occurrence of any individual component of the composite of primary objectives at discharge and 90 days and 1 year after surgery - results in shorter total hospital stay and shorter LOS on ICU, improves functional status and health-related quality of life at 90 days after surgery - reduces the occurrence of acute kidney injury stage I-II defined according to the Kidney Disease Improving Global Outcomes criteria during the initial hospital stay - reduces Re-hospitalisation rate within 90 days after surgery - does not increase occurrence of infections requiring therapeutic intravenous antibiotic treatment (pneumonia, wound infection, sepsis, central line associated blood stream infection) during the initial hospital stay or leading to hospital re-admission within 90 days after surgery.
In addition, the proportion of patients receiving RBC transfusion and the number of units transfused are evaluated. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria for Registration (Step I) 1. Elderly patients (>= 70 years) 2. Undergoing intermediate- or high-risk non-cardiac surgery (according to the ESC/ESA Guidelines: surgery-related risk of cardiovascular death and myocardial infarction) a. Intermediate risk (30-day risk 1-5%): e.g., intraperitoneal (splenectomy, hiatal hernia), peripheral arterial angioplasty, endovascular aneurysm repair, head and neck, major neurological/orthopaedic (hip and spine), major urological, major gynaecological, intra-thoracic surgery b. High-risk (30-day risk > 5%): e.g., aortic and major vascular, open limb revascularisation, (partial) duodeno-pancreatic, (partial) liver resection, oesophagectomy, adrenal or (partial or radical) renal resection, total cystectomy 3. Written informed consent; obtained before surgery from the patients or from their legally authorised representative (authorisation including clinical research/clinical trials) / legal guardian, if the patient is unable to provide informed consent.
Inclusion Criteria for Randomisation (Step II) Registered patients will be randomised only if and as soon as Hb falls <= 9 g/dl (in spite of possible autologous transfusion) during surgery (=day 0) or day 1, 2, or 3 after surgery. If Hb remains > 9 g/dl (even after a two-stage surgery) patient does not enter the main study but vital status (all-cause mortality) will be determined 90 days after surgery
|
|
E.4 | Principal exclusion criteria |
Exclusion Criteria for Registration (Step I) 1. preoperative Hb level <= 9 g/dl 2. chronic kidney disease requiring dialysis 3. suspected lack of compliance with follow-up procedures 4. participation in other interventional trials 5. expected death within 3 months 6. inability to provide informed consent with absence of a legally authorised representative/ legal guardian 7. temporary inability to provide informed consent 8. previous participation in our trial 9. Patients who are prevented from having blood and blood products according to a system of beliefs (e.g. Jehovah’s Witnesses) 10. preoperative autologous blood donation
Exclusion Criteria for Randomisation (Step II) 1. Occurrence of any component of composite endpoint after registration: - Acute myocardial infarction - Acute ischaemic stroke - Acute kidney injury (stage III) - Acute mesenteric ischaemia - Acute peripheral vascular ischaemia 2. Any allogeneic blood transfusion after registration |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy outcome is defined as a composite of (within 90 days after surgery): I. All-cause mortality is defined as death from any cause. II. Acute myocardial infarction confirmed by a cardiologist. III. Acute ischaemic stroke confirmed by a neurologist. IV. Acute kidney injury (stage III) is defined according to the Kidney Disease Improving Global Outcomes criteria: Increase of plasma creatinine level >= 3 times within a time window of 7 days or initiation of renal replacement therapy. (Serum creatinine concentration will be measured at least every 7 days until hospital discharge. Urine output criteria will not be used to define acute kidney injury because most of hospital do not mandate hourly urine output measurements on all patients, and because of the likelihood of inaccurate measurement in the substantial number of patients without urinary catheters.) V. Acute mesenteric ischaemia is defined as ischaemia confirmed by intervention (abdominal surgery or mesenteric angiography). VI. Acute peripheral vascular ischaemia is defined as a new non-thrombotic compromised circulation in a limb confirmed by angiography and/or leading to surgery.
After hospital discharge, events will only be considered as present if they lead to hospital re-admission or death. Direct transfer to another hospital will not be defined as re-admission. Hospital re-admission requires at least one overnight stay in an acute hospital. An ambulatory hospital visit or an admission to a rehabilitation facility or day hospital is not regarded as hospital readmission.
After hospital discharge, the composite endpoint will be assessed by a telephone interview. In cases of inability to follow by telephone, the primary endpoint will be ascertained from participant’s family doctor, or hospital files, respectively. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary outcome measures are the following: - The occurrence of any individual component of the composite of all-cause mortality, acute myocardial infarction, acute stroke, acute kidney injury stage III, acute mesenteric ischaemia, and/or acute peripheral vascular ischaemia at hospital discharge, at 90 days, and 1 year after surgery. - The occurrence of any ischaemic event, i.e., acute myocardial infarction, acute stroke, acute kidney injury stage III, acute mesenteric ischaemia, and/or acute peripheral vascular ischaemia at hospital discharge, at 90 days, and 1 year after surgery, treating all-cause mortality as competing risk. - Proportion of patients receiving RBC transfusion and the number of units transfused. - Total length of stay in the intensive care unit and in hospital from randomisation to discharge (for strategy comparison); in addition, total length of stay in the intensive care unit and in hospital from admission to discharge will be used for descriptive purposes. - The occurrence of acute kidney injury (stage I or II) defined according to the Kidney Disease Improving Global Outcomes criteria (stage I: increase of plasma creatinine level >= 1.5-1.9 times baseline or >= 0.3mg/dl within 48 hours; stage II: increase of plasma creatinine level >= 2-2.9 times baseline within a time window of 7 days) during the initial hospital stay - Time to (first) infection (infection requiring therapeutic intravenous antibiotic treatment (pneumonia, wound infection, sepsis, central line associated blood stream infection)) during the initial hospital stay or leading to hospital re-admission within 90 days after surgery. - Time to (first) Re-hospitalisation within 90 days. - Functional status (assessed by Barthel Index by telephone questionnaire). - Health-related quality of life (assessed by EuroQoL EQ-5D and 12-item World Health Organisation Disability Assessment Schedule WHODAS 2.0) by telephone questionnaire). - Nutritional Risk Screening Score (NRS 2002) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- 90 days after surgery - 1 year after surgery (occurrence of any individual component of the composite only) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
different transfusion strategies: LIBERAL vs. restrictive |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial formally starts with the registration of the first patient (FPI = first patient in), and the formal end of the study is the last 1 year after surgery visit of the last patient randomised (LPO = last patient out). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 100 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 100 |